Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
‘Bespoke Gene Therapy Consortium’ sets out to enable gene therapies for ultra-rare diseases
The NIH and FDA’s newly launched 27-member public–private partnership will spend US$76 million addressing the hurdles of AAV-based gene therapies for ultra-rare diseases.
The Bespoke Gene Therapy Consortium (BGTC) launched in October to bring together 27 partners to ease the roadblocks to gene therapy development for ultra-rare diseases. The 5-year, US$76 million initiative will tackle precompetitive research challenges, establish a standardized development framework, take on manufacturing hurdles and set up a streamlined regulatory path for these agents. The partners include NIH institutes, the FDA, 10 industry players and not-for-profit organizations.